UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2020

LIGHTBRIDGE CORPORATION

(Exact name of registrant as specified in its charter)

	,		,
	Nevada 001-34487 91-1		91-1975651
	(State or other jurisdiction	(Commission	(IRS Employer
	of incorporation)	File Number)	Identification No.)
	1	11710 Plaza America Drive, Suite 200	00
		Reston, VA 20190	
	(Address	of principal executive offices, including	g zip code)
		(571) 730-1200	
	(Registr	rant's Telephone Number, Including Are	ea Code)
	e appropriate box below if the Form 8-K filin provisions:	ng is intended to simultaneously satisfy	y the filing obligation of the registrant under any of the
□ Soli □ Pre- □ Pre-	tten communications pursuant to Rule 425 under to the first pursuant to Rule 14a-12 under the commencement communications pursuant to Recommencement communi	the Exchange Act (17 CFR 240.14a -12) Rule 14d-2(b) under the Exchange Act (Rule 13e-4(c) under the Exchange Act (1) 17 CFR 240.14d -2(b))
Securities	registered pursuant to Section 12(b) of the Act:	:	
	Title of Each Class:	Trading Symbol(s):	Name of Each Exchange on Which Registered:
	Common Stock, \$0.001 par value	Trading Symbol(s): LTBR	The Nasdaq Capital Market
Rule 12b- Emerging If an emer	2 of the Securities Exchange Act of 1934 (17 C growth company □	FR §240.12b-2). if the registrant has elected not to use the	he extended transition period for complying with any new tt. \square

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2020 Lightbridge Corporation issued a press release relating to its results for the third quarter ended September 30, 2020. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 2.02, including the accompanying press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated November 4, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIGHTBRIDGE CORPORATION

Dated: November 4, 2020 By: /s/ Seth Grae

Name: Seth Grae

Title: President and Chief Executive Officer

3



FOR IMMEDIATE RELEASE

Lightbridge Provides Business Update and Announces Third Quarter 2020 Financial Results

Conference Call on Thursday, November 5, 2020 at 4pm ET

RESTON, Va., November 4, 2020 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ: LTBR), an advanced nuclear fuel technology company, today announced financial results for the third quarter ended September 30, 2020, as well as the Company's corporate progress and other meaningful developments.

Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, "I'm pleased with the progress that Lightbridge has made in the third quarter, particularly in our performance under our CRADA agreement with Idaho National Laboratory (INL), in collaboration with the U.S. Department of Energy (DOE). Our team has worked diligently with INL to navigate this initial process, and we are optimistic about the prospects for the success of this program. We expect that this GAIN voucher that provides over \$600,000 from DOE is the first of a series of U.S. government funding opportunities. DOE notes that funding awards over \$500,000, are made 'in cases with a clear need and involving a truly exceptional technology or innovation.'

"In addition, Lightbridge continues to be well positioned financially. Our strong cash position of \$17.4 million as of September 30, 2020 and no debt, provides us the financial resources to fund our ongoing fuel development efforts throughout 2021, while pursuing additional opportunities towards commercializing Lightbridge FuelTM.

"This is an exciting time for Lightbridge, as well as for the U.S. nuclear power industry. We are seeing increasing bipartisan governmental support for advanced nuclear technologies. The U.S. government is taking concrete steps to assure that nuclear innovations being developed by American companies compete and win in the global market, particularly in competition with Chinese and Russian state-owned enterprises. We are working towards being one of the companies that will help implement these long-term strategic goals."

Financial Highlights

The Company maintains a strong working capital position of \$15.8 million at September 30, 2020 and has no debt.

Cash Flows Summary

- Total cash used for the nine months ended September 30, 2020 was \$0.6 million compared to \$4.1 million for the nine months ended September 30, 2019. This decrease consisted of the following:
 - Cash used in operating activities increased approximately \$1.5 million for the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019, primarily due to an increase in general and administrative expenses (see operations summary below) offset by a decrease in our research and development expenses, as Lightbridge is no longer conducting its research and development activities through Enfission.
 - · Cash used in investing activities decreased by approximately \$3.6 million for the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019, primarily due to the inactive status of the Enfission joint venture resulting in no capital contributions being made to Enfission in 2020.
 - Cash provided by financing activities increased by approximately \$1.4 million for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019, primarily due to the increase in the net proceeds from issuance of common stock in 2020, which was \$5.2 million for the nine months ended September 30, 2020 as compared to \$3.8 million net proceeds for the nine months ended September 30, 2019.

Balance Sheet Summary

- · Cash and cash equivalents were \$17.4 million at September 30, 2020, as compared to \$18 million at December 31, 2019, a decrease of \$0.6 million in cash and cash equivalents for the nine months ended September 30, 2020.
- Total assets were \$19.4 million and total liabilities were \$1.8 million at September 30, 2020. Working capital was \$15.8 million at September 30, 2020 versus \$18.1 million at December 31, 2019. This decrease of \$2.3 million in working capital was due primarily to the factors stated above in the cash flows summary.
- · Stockholders' equity was \$17.6 million at September 30, 2020 versus \$19.9 million at December 31, 2019. This decrease of \$2.3 million was primarily due to the net loss reported for the nine months ended September 30, 2020 of \$7.5 million, offset by the increase in capital related to the sale of common stock of approximately \$5.2 million.

Operations Summary

- General and administrative expenses increased by approximately \$1.4 million for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019. There was an increase in professional fees of approximately \$1.3 million primarily due to legal fees relating to the Framatome arbitration and a net increase in employee compensation and employee benefits of approximately \$0.1 million.
- Research and development expenses decreased by approximately \$0.5 million for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019, due to the transitioning from work relating to Enfission to developing a new fuel development strategy with U.S. Department of Energy national laboratories. There was a decrease in allocated employee compensation and employee benefits of approximately \$0.4 million and a decrease in consulting fees of \$0.1 million.
- There was a decrease in other operating income (loss) of approximately \$0.3 million, due a decrease in the equity in loss recorded from the Enfission joint venture of \$0.6 million, which consisted primarily of research and development expenses, offset by no consulting services performed by Lightbridge on behalf of Enfission for the three months ended September 30, 2020, as compared to \$0.3 million for the three months ended September 30, 2019.
- There was a decrease in other income of approximately \$0.1 million due to a decrease in interest income generated from the interest earned from the purchase of treasury bills and from our bank savings account for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019.
- Net loss for the three months ended September 30, 2020 was \$3.1 million compared to \$2.4 million for the three months ended September 30, 2019. This increase of \$0.7 million was primarily due to the factors stated above in this operations summary.

THIRD QUARTER CONFERENCE CALL & WEBCAST

Lightbridge will host a conference call on Thursday, November 5th at 4:00 p.m. Eastern Time to discuss the Company's financial results for the third quarter ended September 30, 2020, as well as the Company's corporate progress and other meaningful developments.

Interested parties can access the conference call by calling 833-519-1295 for U.S. callers, or +1-914-800-3866 for international callers. Please reference Conference ID: 8391229. The call will be available on the Company's website via webcast at https://edge.media-server.com/mmc/p/6678p764. The conference call will be led by Seth Grae, President and Chief Executive Officer, and other Lightbridge executives will also be available to answer questions.

A webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately two hours following the call and can be accessed by dialing 855-859-2056 from the U.S. or +1-404-537-3406 for international callers. Please reference Conference ID: 8391229.

About Lightbridge Corporation

Lightbridge (NASDAQ: LTBR) is an advanced nuclear fuel technology development company based in Reston, Virginia, United States. The Company is developing Lightbridge FuelTM, a proprietary next-generation nuclear fuel technology for current and future reactors, which significantly enhances the economics, safety, and proliferation resistance of nuclear power. Lightbridge invented, patented, and has independently validated its technology, with goals of preventing climate change and enhancing national security. The Company has assembled a world-class development team. Four large electric utilities that generate about half of America's nuclear power advise Lightbridge on fuel development and deployment. The Company plans to operate under a licensing and royalty model and based on the increased power generated by Lightbridge-designed fuel, expects to offer high ROI for operators of existing and new reactors. For more information please visit: www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at https://www.ltbridge.com/investors/news-events/email-alerts

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Forward Looking Statements

With the exception of historical matters, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing and outcome of research and development activities, other steps to commercialize Lightbridge Fuel™ and future governmental support and funding for nuclear energy. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to: the Company's ability to commercialize its nuclear fuel technology; the degree of market adoption of the Company's product and service offerings; market competition; dependence on strategic partners; demand for fuel for nuclear reactors; the Company's ability to manage its business effectively in a rapidly evolving market; changes in the political environment; risks associated with the further spread of COVID-19, including the ultimate impact of COVID-19 on people, economies, and the Company's ability to access capital markets; the outcome of the arbitration with the Company's former joint venture partner and dissolution of the Enfission joint venture; as well as other factors described in Lightbridge's filings with the U.S. Securities and Exchange Commission. Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise, except as required by law. Readers are cautioned not to put undue reliance on forward-looking statements.

A further description of risks and uncertainties can be found in Lightbridge's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov/ and www.ltbridge.com.

Investor Relations Contact:

Matthew Abenante, IRC Director of Investor Relations Tel: +1 (646) 828-8710 ir@ltbridge.com

*** tables follow ***

LIGHTBRIDGE CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	Sept		D	December 31 2019	
ASSETS	_				
Current Assets					
Cash and cash equivalents	\$	17,410,899	\$	17,958,989	
Other receivable from joint venture		_		400,000	
Prepaid expenses and other current assets		164,652		47,371	
Total Current Assets		17,575,551		18,406,360	
Other Assets					
Patent costs		1,825,326		1,798,484	
Total Assets	\$	19,400,877	\$	20,204,844	
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current Liabilities					
Accounts payable and accrued liabilities	\$	1,815,791	\$	350,299	
Total Current Liabilities		1,815,791		350,299	
Commitments and contingencies					
Stockholders' Equity					
Preferred stock, \$0.001 par value, 10,000,000 authorized shares:					
Convertible Series A preferred shares, 712,126 and 757,770 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively (liquidation preference \$2.612,802 and \$2.636,764 at September 30, 2020					
and December 31, 2019, respectively)		712		75	
Convertible Series B preferred shares, 2,666,667 issued and outstanding at September 30, 2020 and December 31, 2019, (liquidation preference \$4,813,284 and \$4,569,180 at September 30, 2020 and December 31, 2019,					
respectively)		2,667		2,667	
Common stock, \$0.001 par value, 8,333,333 authorized, 4,416,961 and 3,252,371 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively		4,417		3,252	
Additional paid-in capital		139,121,290		133,932,615	
Accumulated deficit		(121,544,000)		(114,084,746	
Total Stockholders' Equity		17,585,086		19,854,54	
rotal blockholders Equity	\$	19,400,877	\$	20,204,844	
Total Liabilities and Stockholders' Equity			٠.	ZU.ZU4.844	

LIGHTBRIDGE CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended September 30,				Nine Months Ended September 30,			
		2020		2019		2020		2019
Revenue	\$	_	\$		\$	_	\$	_
Operating Expenses								
General and administrative		2,835,471		1,463,568		6,800,892		4,051,484
Research and development		261,898		751,473		767,498		2,218,826
Total Operating Expenses		3,097,369	_	2,215,041	_	7,568,390	_	6,270,310
Other Operating Income and (Loss)								
Grant income		29,662		_		29,662		_
Other income from joint venture		_		247,568		_		908,224
Equity in loss from joint venture		_		(555,113)		_		(3,812,463)
Total Other Operating Income and (Loss)		29,662		(307,545)		29,662		(2,904,239)
Operating Loss		(3,067,707)		(2,522,586)		(7,538,728)		(9,174,549)
Other Income								
Interest income		4,645		81,172		79,474		315,691
Total Other Income		4,645		81,172	_	79,474		315,691
Loss before income taxes		(3,063,062)		(2,441,414)		(7,459,254)		(8,858,858)
Income taxes		(c,:::,::=)				(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		(c,crc,crc)
Net Loss	\$	(3,063,062)	\$	(2,441,414)	\$	(7,459,254)	\$	(8,858,858)
Accumulated preferred stock dividend		(128,937)		(123,455)		(383,086)		(365,973)
Deemed additional dividend on preferred stock dividend due the beneficial		(-,)		(-,,		(= ,)		(= == ,= =)
conversion feature		(55,940)		(53,047)		(165,551)		(156,232)
Net loss attributable to common stockholders	\$	(3,247,939)	\$	(2,617,916)	\$	(8,007,891)	\$	(9,381,063)
Net Loss Per Common Share								
Basic and Diluted	\$	(0.80)	\$	(0.81)	\$	(2.22)	\$	(3.07)
Weighted Average Number of Common Shares Outstanding	*	4,053,644	_	3,222,226	-	3,613,349	-	3,058,797

LIGHTBRIDGE CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Adjustments to reconcile net loss from operations to net cash used in operating activities 25,110 591,6 Patent write-off Patent write-off Equity in loss from joint venture 3,812,4 Changes in operating working capital items:		Nine Months Ended September 30,			
Net Loss \$ (7,459,254) \$ (8,858.8.8.4) Adjustments to reconcile net loss from operations to net cash used in operating activities 25,110 591,6 Common stock issued for services and stock-based compensation 25,110 591,6 Patent write-off 111,850 - 3,812,4 Equity in loss from joint venture 400,000 (540,12) Changes in operating working capital items: - 140,000 (540,12) Other receivable from joint venture 400,000 (540,12) Prepaid expenses and other current assets (117,281) (60,22) Accounts payable and accrued liabilities 1,465,492 937,8 Net Cash Used in Operating Activities - 3,540,00 Investing Activities - 3,540,00 Patent costs (138,692) (148,4 Net Cash Used in Investing Activities (138,692) (148,4 Net Proceeds from issuances of common stock and exercise of stock options 5,164,685 3,750,4 Net Cash Provided by Financing Activities 5,164,685 3,750,4 Net Decrease in Cash and Cash Equivalents (548,090) <t< th=""><th></th><th></th><th>2020</th><th></th><th>2019</th></t<>			2020		2019
Adjustments to reconcile net loss from operations to net cash used in operating activities 25,110 591,6 Patent write-off 111,850 - Equity in loss from joint venture 3,812,4 Changes in operating working capital items: - 3,812,4 Other receivable from joint venture 400,000 540,1 Prepaid expenses and other current assets (117,281) (60,2 Accounts payable and accrued liabilities 1,465,492 93,84 Net Cash Used in Operating Activities (5,574,083) (4,117,3 Investing Activities (138,692) (148,4 Net Cash Used in Investing Activities (138,692) (3,540,0 Patent costs (138,692) (148,4 Net Cash Used in Investing Activities (138,692) (3,688,4 Financing Activities 5,164,685 3,750,4 Net Decrease in Cash and Cash Equivalents 5,164,685 3,750,4 Net Decrease in Cash and Cash Equivalents (548,090) 4,055,3 Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,2 Cash and Cash Equivalents, End of Period 17,	Operating Activities				
Common stock issued for services and stock-based compensation 25,110 591,66 Pattent write-off 111,850 - 3,812,46 Equity in loss from joint venture - 3,812,46 Changes in operating working capital items: - 400,000 (540,11 Prepaid expenses and other current assets (117,281) (60,22 Accounts payable and accrued liabilities 1,465,492 937,8 Net Cash Used in Operating Activities - (3,540,0 Investing Activities - (3,540,0 Investing Activities - (3,540,0 Patent costs (138,692) (148,4 Net Cash Used in Investing Activities (138,692) (3,688,4 Net Cash Used in Investing Activities (138,692) (3,688,4 Financing Activities - (3,540,0 Net Cash Used in Investing Activities 5,164,685 3,750,4 Net Cash Provided by Financing Activities 5,164,685 3,750,4 Net Cash Provided by Financing Activities (548,090) (4,055,3 Cash and Cash Equivalents, End of Period 17,958,98		\$	(7,459,254)	\$	(8,858,858)
Patent write-off 111,850 — 3,812,41 Equity in loss from joint venture — 3,812,41 Changes in operating working capital items: — 400,000 (540,11) Other receivable from joint venture 400,000 (540,11) Prepaid expenses and other current assets (117,281) (60,22) Accounts payable and accrued liabilities 1,465,492 937.8 Net Cash Used in Operating Activities (5,574,083) (4,117.3) Investing Activities — (3,540,00) Patent costs (138,692) (148,4) Net Cash Used in Investing Activities (138,692) (148,4) Financing Activities — (13,540,00) (3,584,00) Net Cash Used in Investing Activities 5,164,685 3,750,4 Net Provided by Financing Activities 5,164,685 3,750,4 Net Cash Provided by Financing Activities 5,164,685 3,750,4 Net Decrease in Cash and Cash Equivalents (548,090) (4,055,3) Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,29 Cash and Cash Equivalents, End of Period 17,910,899 20,581,99					
Equity in loss from joint venture 3,812,46 Changes in operating working capital items: 400,000 (540,15 Other receivable from joint venture 400,000 (540,15 Prepaid expenses and other current assets (117,281) (60,22 Accounts payable and accrued liabilities 1,465,492 937,8 Net Cash Used in Operating Activities (5,574,083) (4,117,3) Investing Activities - 3,540,0 Investing Activities - 3,540,0 Patent costs (138,692) (148,4 Net Cash Used in Investing Activities (138,692) (148,4 Net Cash Used in Investing Activities (138,692) (3,540,0 Patent costs (138,692) (148,4 Net Cash Used in Investing Activities 5,164,685 3,750,4 Net Proceeds from issuances of common stock and exercise of stock options 5,164,685 3,750,4 Net Cash Provided by Financing Activities (548,090) (4,055,3 Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,2 Cash and Cash Equivalents, End of Period 17,410,899			,		591,663
Changes in operating working capital items: 400,000 (540,11 (60,22			111,850		
Other receivable from joint venture 400,000 (540,1) Prepaid expenses and other current assets (117,281) (60,2) Accounts payable and accrued liabilities 1,465,492 937,8 Net Cash Used in Operating Activities (5,574,083) (4,117,3) Investing Activities — (3,540,00) Investment in joint venture — (3,540,00) Patent costs (138,692) (148,4) Net Cash Used in Investing Activities (138,692) (3,688,4) Financing Activities — (3,540,00) Net proceeds from issuances of common stock and exercise of stock options 5,164,685 3,750,4 Net Decrease in Cash and Cash Equivalents (548,090) (4,055,3) Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,2 Cash and Cash Equivalents, End of Period \$ 17,410,899 \$ 20,581,9 Supplemental Disclosure of Cash Flow Information \$ 17,410,899 \$ 20,581,9 Supplemental Disclosure of Cash Flow Information \$ 17,410,899 \$ 20,581,9 Supplemental Disclosure of Cash Flow Information \$ 17,410,899 \$ 20,581,9 Supplemental Disclosure of Cash Flow Information \$ 17,410,899 \$ 20,581,9 Cash paid during the period \$ 17,410,899 \$ 20,581,9 Income taxes			_		3,812,463
Prepaid expenses and other current assets (117,281) (60,2) Accounts payable and accrued liabilities 1,465,492 937,8 Net Cash Used in Operating Activities (5,574,083) (4,117,3) Investing Activities - (3,540,00) Patent costs (138,692) (148,4) Net Cash Used in Investing Activities (138,692) (3,688,4) Financing Activities (138,692) (3,688,4) Net Provided by Financing Activities 5,164,685 3,750,4 Net Decrease in Cash and Cash Equivalents (548,090) (4,055,3) Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,20 Cash and Cash Equivalents, End of Period \$ 17,410,899 \$ 20,581,90 Supplemental Disclosure of Cash Flow Information \$ 17,410,899 \$ 20,581,90 Cash paid during the period \$ 17,410,899 \$ 20,581,90 Income taxes paid \$ 2 \$ 2 Non-Cash Financing Activities \$ 2 \$ 2 Accumulated preferred stock dividend \$ 548,637 \$ 522,20 Conversion of Series A convertible preferred stock to common stoc					
Accounts payable and accrued liabilities 1,465,492 937.8 Net Cash Used in Operating Activities (5,574,083) (4,117.3) Investing Activities 3,540,00 (138,692) (148,40) Patent costs (138,692) (148,40) (138,692) (148,40) Net Cash Used in Investing Activities 5,164,685 3,750,40 (138,692) (3,688,40) Financing Activities 5,164,685 3,750,40 (3,540,60) (3,540,60) (3,688,40) (3,688,40) (3,688,40) (4,055,30) <t< td=""><td></td><td></td><td>,</td><td></td><td>(540,155)</td></t<>			,		(540,155)
Net Cash Used in Operating Activities (5,574,083) (4,117,33) Investing Activities (3,540,00) (3,540,00) (148,40) (148			. , ,		(60,288)
Investment in joint venture			1,465,492		937,836
Investment in joint venture Patent costs (138,692) (148,49) Ret Cash Used in Investing Activities (138,692) (3,688,49) Financing Activities Net proceeds from issuances of common stock and exercise of stock options Net Cash Provided by Financing Activities Net Decrease in Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Net Cash Used in Operating Activities	_	(5,574,083)	_	(4,117,339)
Investment in joint venture Patent costs (138,692) (148,49) Ret Cash Used in Investing Activities (138,692) (3,688,49) Financing Activities Net proceeds from issuances of common stock and exercise of stock options Net Cash Provided by Financing Activities Net Decrease in Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Investing Activities				
Patent costs (138,692) (148,42) Net Cash Used in Investing Activities (138,692) (3,688,42) Financing Activities 5,164,685 3,750,42 Net proceeds from issuances of common stock and exercise of stock options 5,164,685 3,750,42 Net Cash Provided by Financing Activities 5,164,685 3,750,42 Net Decrease in Cash and Cash Equivalents (548,090) (4,055,3 Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,29 Supplemental Disclosure of Cash Flow Information \$ 17,410,899 \$ 20,581,99 Supplemental Disclosure of Cash Flow Information \$ - \$ - Cash paid during the period \$ - \$ - Income taxes paid \$ - \$ - Non-Cash Financing Activities \$ - \$ - Accumulated preferred stock dividend \$ 548,637 \$ 522,29 Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to \$ 10,000 \$ 10,000			_		(3,540,000)
Financing Activities Net proceeds from issuances of common stock and exercise of stock options Net Cash Provided by Financing Activities Net Decrease in Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Patent costs		(138,692)		(148,432)
Net proceeds from issuances of common stock and exercise of stock options Net Cash Provided by Financing Activities 5,164,685 3,750,43 Net Cash Provided by Financing Activities Net Decrease in Cash and Cash Equivalents (548,090) (4,055,3 Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,29 Cash and Cash Equivalents, End of Period \$ 17,410,899 \$ 20,581,99 Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Net Cash Used in Investing Activities		(138,692)		(3,688,432)
Net proceeds from issuances of common stock and exercise of stock options Net Cash Provided by Financing Activities 5,164,685 3,750,42 Net Decrease in Cash and Cash Equivalents (548,090) (4,055,3 Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,22 Cash and Cash Equivalents, End of Period \$17,410,899 \$20,581,92 Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Financing Activities				
Net Cash Provided by Financing Activities 5,164,685 3,750,4 Net Decrease in Cash and Cash Equivalents (548,090) (4,055,3 Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,29 Cash and Cash Equivalents, End of Period \$17,410,899 \$20,581,99 Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to			5 164 685		3 750 454
Net Decrease in Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,29 Cash and Cash Equivalents, End of Period \$ 17,410,899 \$ 20,581,99 Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to					
Cash and Cash Equivalents, Beginning of Period 17,958,989 24,637,29 Cash and Cash Equivalents, End of Period \$ 17,410,899 \$ 20,581,99 Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Net Cash Flovided by Financing Activities	_	3,104,063		3,730,434
Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Net Decrease in Cash and Cash Equivalents		(548,090)		(4,055,317)
Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Cash and Cash Equivalents, Beginning of Period		17,958,989		24,637,295
Supplemental Disclosure of Cash Flow Information Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Cash and Cash Equivalents End of Period	S	17.410.899	\$	20,581,978
Cash paid during the period Interest paid Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Cash and Cash Equitation, End of Forest	<u> </u>	17,110,055		20,001,570
Interest paid \$ \$ \$ Income taxes paid \$ \$ \$ Non-Cash Financing Activities Accumulated preferred stock dividend \$ 548,637 \$ 522,20 Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Supplemental Disclosure of Cash Flow Information				
Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Cash paid during the period				
Income taxes paid Non-Cash Financing Activities Accumulated preferred stock dividend Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Interest paid	\$	_	\$	_
Accumulated preferred stock dividend \$ 548,637 \$ 522,20 Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Income taxes paid	\$		\$	
Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to	Non-Cash Financing Activities				
	Accumulated preferred stock dividend	\$	548,637	\$	522,205
	Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to				
Series A preferred stockholder \$ 38,071 \$ 91,60		\$	38,071	\$	91,635
Common stock issued for services \$ 17,000 \$ -	1	\$	17,000	\$	